Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

US pol­i­cy­mak­ers and pay­ers should con­sid­er in­di­ca­tion-based pric­ing in a bid to cut down on high­er can­cer drug costs in the US, ac­cord­ing to re­search

CMS did not make a na­tion­al cov­er­age de­ter­mi­na­tion for PrEP by the ex­pect­ed date of Oct. 10, but a fi­nal de­ci­sion will be com­ing lat­er,